Newland Pharmaceutical Co., Ltd. (SHE:301277)
China
· Delayed Price · Currency is CNY 12.31
-0.08 (-0.65%)
Mar 9, 2026, 4:00 PM EDT
Newland Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Operating Revenue | 663.43 | 719.43 | 643.85 | 621.21 | 508.93 | 429.75 | Upgrade
|
| Other Revenue | 7 | 7 | 7.59 | 6.15 | 4.91 | 3.38 | Upgrade
|
| Revenue | 670.43 | 726.44 | 651.44 | 627.36 | 513.84 | 433.12 | Upgrade
|
| Revenue Growth (YoY) | -4.03% | 11.51% | 3.84% | 22.09% | 18.63% | 6.54% | Upgrade
|
| Cost of Revenue | 429.2 | 437.43 | 392.84 | 404.01 | 307.82 | 236.31 | Upgrade
|
| Gross Profit | 241.23 | 289 | 258.6 | 223.36 | 206.02 | 196.81 | Upgrade
|
| Selling, General & Admin | 55.48 | 47.62 | 44.49 | 38.83 | 31.56 | 25.3 | Upgrade
|
| Research & Development | 53.65 | 55.49 | 51.96 | 30 | 20.59 | 20.62 | Upgrade
|
| Other Operating Expenses | 6.51 | 2.71 | 3.89 | 6.99 | 6.4 | 5.83 | Upgrade
|
| Operating Expenses | 115.18 | 108.1 | 96.75 | 78.04 | 69.69 | 53.99 | Upgrade
|
| Operating Income | 126.05 | 180.91 | 161.85 | 145.31 | 136.33 | 142.82 | Upgrade
|
| Interest Expense | -0.06 | -0.09 | -0.13 | -6.88 | -6.71 | -3.8 | Upgrade
|
| Interest & Investment Income | 12.83 | 16.7 | 19.63 | 1.34 | 0.26 | 0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.25 | 0.25 | 0.06 | 0.29 | -0.13 | -0.35 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.65 | -0.06 | -0.12 | -0.09 | -0.06 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | 142.71 | 197.7 | 181.29 | 139.97 | 129.69 | 138.74 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.09 | -0.23 | 0.04 | 1.36 | 0.17 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.07 | -0.44 | -0.21 | -0.12 | Upgrade
|
| Asset Writedown | -3.36 | -2.62 | -1.46 | -0.32 | -0.11 | - | Upgrade
|
| Legal Settlements | - | - | - | - | - | -3 | Upgrade
|
| Other Unusual Items | 1.86 | 2.5 | 1.22 | 2.31 | 2.4 | 1.81 | Upgrade
|
| Pretax Income | 140.12 | 197.35 | 181.16 | 142.88 | 131.94 | 137.43 | Upgrade
|
| Income Tax Expense | 17.72 | 24.34 | 23.96 | 11.17 | 17.11 | 18.97 | Upgrade
|
| Earnings From Continuing Operations | 122.41 | 173.01 | 157.2 | 131.71 | 114.82 | 118.46 | Upgrade
|
| Minority Interest in Earnings | 1.31 | 0.62 | 1.78 | 0.6 | 0.15 | - | Upgrade
|
| Net Income | 123.72 | 173.63 | 158.98 | 132.3 | 114.98 | 118.46 | Upgrade
|
| Net Income to Common | 123.72 | 173.63 | 158.98 | 132.3 | 114.98 | 118.46 | Upgrade
|
| Net Income Growth | -24.61% | 9.21% | 20.16% | 15.07% | -2.94% | 8.52% | Upgrade
|
| Shares Outstanding (Basic) | 392 | 392 | 391 | 302 | 294 | 292 | Upgrade
|
| Shares Outstanding (Diluted) | 392 | 392 | 391 | 302 | 294 | 292 | Upgrade
|
| Shares Change (YoY) | 0.39% | 0.39% | 29.52% | 2.59% | 0.64% | 0.34% | Upgrade
|
| EPS (Basic) | 0.32 | 0.44 | 0.41 | 0.44 | 0.39 | 0.41 | Upgrade
|
| EPS (Diluted) | 0.32 | 0.44 | 0.41 | 0.44 | 0.39 | 0.40 | Upgrade
|
| EPS Growth | -24.91% | 8.79% | -7.22% | 12.17% | -3.36% | 8.18% | Upgrade
|
| Free Cash Flow | 16.5 | 15.97 | 162.94 | 8.5 | 23.68 | 30.9 | Upgrade
|
| Free Cash Flow Per Share | 0.04 | 0.04 | 0.42 | 0.03 | 0.08 | 0.11 | Upgrade
|
| Dividend Per Share | 0.286 | 0.286 | 0.204 | 0.170 | - | - | Upgrade
|
| Dividend Growth | 39.98% | 39.98% | 19.99% | - | - | - | Upgrade
|
| Gross Margin | 35.98% | 39.78% | 39.70% | 35.60% | 40.09% | 45.44% | Upgrade
|
| Operating Margin | 18.80% | 24.90% | 24.85% | 23.16% | 26.53% | 32.98% | Upgrade
|
| Profit Margin | 18.45% | 23.90% | 24.40% | 21.09% | 22.38% | 27.35% | Upgrade
|
| Free Cash Flow Margin | 2.46% | 2.20% | 25.01% | 1.35% | 4.61% | 7.13% | Upgrade
|
| EBITDA | 165.82 | 215.99 | 190.69 | 167.38 | 157.19 | 160.77 | Upgrade
|
| EBITDA Margin | 24.73% | 29.73% | 29.27% | 26.68% | 30.59% | 37.12% | Upgrade
|
| D&A For EBITDA | 39.77 | 35.09 | 28.84 | 22.06 | 20.86 | 17.95 | Upgrade
|
| EBIT | 126.05 | 180.91 | 161.85 | 145.31 | 136.33 | 142.82 | Upgrade
|
| EBIT Margin | 18.80% | 24.90% | 24.85% | 23.16% | 26.53% | 32.98% | Upgrade
|
| Effective Tax Rate | 12.64% | 12.33% | 13.23% | 7.82% | 12.97% | 13.80% | Upgrade
|
| Revenue as Reported | 670.43 | 726.44 | 651.44 | 627.36 | 513.84 | - | Upgrade
|
| Advertising Expenses | - | 0.85 | 0.51 | 0.2 | 0.28 | 0.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.